11/26
08:05 am
rigl
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
11/25
06:03 pm
rigl
Rigel Pharmaceuticals: Behind The Huge Rally [Seeking Alpha]
Low
Report
Rigel Pharmaceuticals: Behind The Huge Rally [Seeking Alpha]
11/17
08:21 am
rigl
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology [Yahoo! Finance]
Low
Report
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology [Yahoo! Finance]
11/17
08:05 am
rigl
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
Low
Report
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
11/12
08:05 am
rigl
Rigel to Present at the Jefferies Global Healthcare Conference in London
Medium
Report
Rigel to Present at the Jefferies Global Healthcare Conference in London
11/11
02:40 pm
rigl
Rigel Pharmaceuticals (RIGL) Is Up 21.7% After Strong Q3 Results and Raised 2025 Guidance [Yahoo! Finance]
Low
Report
Rigel Pharmaceuticals (RIGL) Is Up 21.7% After Strong Q3 Results and Raised 2025 Guidance [Yahoo! Finance]
11/9
09:48 pm
rigl
Rigel Pharmaceuticals (RIGL): Assessing Valuation Following Record Q3 Results and Raised 2025 Outlook [Yahoo! Finance]
Medium
Report
Rigel Pharmaceuticals (RIGL): Assessing Valuation Following Record Q3 Results and Raised 2025 Outlook [Yahoo! Finance]
11/7
06:19 am
rigl
Rigel Pharmaceuticals (NASDAQ:RIGL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Rigel Pharmaceuticals (NASDAQ:RIGL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
11/5
04:31 pm
rigl
Rigel Pharmaceuticals (NASDAQ:RIGL) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $42.00 price target on the stock.
Medium
Report
Rigel Pharmaceuticals (NASDAQ:RIGL) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $42.00 price target on the stock.
11/5
10:49 am
rigl
Rigel Pharmaceuticals (NASDAQ:RIGL) had its price target raised by analysts at Cantor Fitzgerald from $32.00 to $38.00. They now have a "neutral" rating on the stock.
Low
Report
Rigel Pharmaceuticals (NASDAQ:RIGL) had its price target raised by analysts at Cantor Fitzgerald from $32.00 to $38.00. They now have a "neutral" rating on the stock.
11/4
04:01 pm
rigl
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
High
Report
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
11/3
09:05 am
rigl
Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
Low
Report
Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
10/29
08:05 am
rigl
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
Low
Report
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
10/12
06:29 am
rigl
How Rigel Pharmaceuticals' R289 Trial Progress and FDA Designations Will Impact RIGL Investors [Yahoo! Finance]
Medium
Report
How Rigel Pharmaceuticals' R289 Trial Progress and FDA Designations Will Impact RIGL Investors [Yahoo! Finance]
10/8
10:22 am
rigl
Rigel Pharmaceuticals (NASDAQ:RIGL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Medium
Report
Rigel Pharmaceuticals (NASDAQ:RIGL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
10/8
08:19 am
rigl
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS [Yahoo! Finance]
Medium
Report
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS [Yahoo! Finance]
10/8
08:05 am
rigl
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
Medium
Report
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
10/8
07:29 am
rigl
Rigel Pharmaceuticals (NASDAQ:RIGL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Rigel Pharmaceuticals (NASDAQ:RIGL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
10/3
08:05 am
rigl
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
9/25
10:54 pm
rigl
Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion [Seeking Alpha]
Low
Report
Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion [Seeking Alpha]
9/19
02:28 am
rigl
What Does Wall Street Think About Rigel Pharmaceuticals (RIGL)? [Yahoo! Finance]
Neutral
Report
What Does Wall Street Think About Rigel Pharmaceuticals (RIGL)? [Yahoo! Finance]
9/9
07:13 am
rigl
A Look At The Intrinsic Value Of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) [Yahoo! Finance]
High
Report
A Look At The Intrinsic Value Of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) [Yahoo! Finance]